NVO
Novo Nordisk A/S
NYSE: NVO · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$42.22
+4.79% today
Updated 2026-04-30
Market cap
$182.60B
P/E ratio
11.40
P/S ratio
0.59x
EPS (TTM)
$3.61
Dividend yield
4.38%
52W range
$35 – $78
Volume
21.0M
WallStSmart proprietary scores
55
out of 100
Grade: C+
Hold
Investment rating
4.7
Growth
C4.8
Quality
C10.0
Profitability
A+5.7
Valuation
C+3/9
Piotroski F-Score
Weak
2.1
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$46.65
+10.49%
12-Month target
$36.86
-12.70%
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy4 Buy9 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Profit margin 33.10% — above average
+ ROE 60.70% — strong efficiency
Risks
- Piotroski 3/9 — weak financial health
- Negative free cash flow $-36.22B
- Revenue declining -7.60% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $176.95B | $232.26B | $290.40B | $309.06B | $309.06B | $296.9B |
| Net income | $55.52B | $83.68B | $100.99B | $102.43B | $26.89B | — |
| EPS | — | — | — | — | $3.61 | $22.12 |
| Free cash flow | $64.13B | $70.01B | $69.66B | $28.99B | $-36.22B | — |
| Profit margin | 31.38% | 36.03% | 34.78% | 33.14% | 33.10% | — |
Peer comparison
Smart narrative
Novo Nordisk A/S trades at $42.22. representing a P/E of 11.40x trailing earnings. Our Smart Value Score of 55/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 2.13, it sits in the grey zone. TTM revenue stands at $309.06B. with profit margins at 33.10%.
Frequently asked questions
What is Novo Nordisk A/S's stock price?
Novo Nordisk A/S (NVO) trades at $42.22.
Is Novo Nordisk A/S overvalued?
Smart Value Score 55/100 (Grade C+, Hold).
What is the price target of Novo Nordisk A/S (NVO)?
The analyst target price is $46.65, representing +10.5% upside from the current price of $42.22.
What is the future stock price of NVO by 2030?
Our research-backed model estimates Novo Nordisk A/S could reach $1,065.02 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Novo Nordisk A/S's revenue?
TTM revenue is $309.06B.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
2.13 — grey zone.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio0.59x
ROE60.70%
Beta0.27
50D MA$39.38
200D MA$50.75
Shares out3.36B
Float3.19B
Short ratio—
Avg volume21.0M
Performance
1 week+2.55%
1 month+15.73%
3 months-28.96%
YTD-17.02%
1 year—
3 years—
5 years—